Retraction notices

Stereotactic body radiotherapy plus pembrolizumab and trametinib versus stereotactic body radiotherapy plus gemcitabine for locally recurrent pancreatic cancer after surgical resection: an open-label, randomised, controlled, phase 2 trial

Type

Retraction

Notice date

3/9/2022 0:00

Journal

Lancet

Publisher

Elsevier

Notice DOI

10.1016/s1470-2045(22)00064-x

Original paper DOI

10.1016/s1470-2045(21)00286-2

Reasons

• Error in Analyses
• Error in Methods
• Error in Results and/or Conclusions
• Retract and Replace